Andrew Berchuck
Overview:
Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).
Positions:
James M. Ingram Distinguished Professor of Gynecologic Oncology
Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine
Professor of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine
Chief of Gynecologic Oncology
Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
M.D. 1980
Case Western Reserve University
Grants:
A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities
Administered By
Population Health Sciences
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
Endometrial Cancer TCGA Project
Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors
Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date
Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors
Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
MD Anderson Cancer Center
Role
Principal Investigator
Start Date
End Date
TGCA Purchase Order
Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
Leidos Biomedical Research, Inc.
Role
Principal Investigator
Start Date
End Date
Publications:
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
BACKGROUND: Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort. METHODS: Single nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types. RESULTS: We identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P < .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P < .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types. CONCLUSIONS: CNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.
Authors
DeVries, AA; Dennis, J; Tyrer, JP; Peng, P-C; Coetzee, SG; Reyes, AL; Plummer, JT; Davis, BD; Chen, SS; Dezem, FS; Aben, KKH; Anton-Culver, H; Antonenkova, NN; Beckmann, MW; Beeghly-Fadiel, A; Berchuck, A; Bogdanova, NV; Bogdanova-Markov, N; Brenton, JD; Butzow, R; Campbell, I; Chang-Claude, J; Chenevix-Trench, G; Cook, LS; DeFazio, A; Doherty, JA; Dörk, T; Eccles, DM; Eliassen, AH; Fasching, PA; Fortner, RT; Giles, GG; Goode, EL; Goodman, MT; Gronwald, J; OPAL Study Group,; AOCS Group,; Håkansson, N; Hildebrandt, MAT; Huff, C; Huntsman, DG; Jensen, A; Kar, S; Karlan, BY; Khusnutdinova, EK; Kiemeney, LA; Kjaer, SK; Kupryjanczyk, J; Labrie, M; Lambrechts, D; Le, ND; Lubiński, J; May, T; Menon, U; Milne, RL; Modugno, F; Monteiro, AN; Moysich, KB; Odunsi, K; Olsson, H; Pearce, CL; Pejovic, T; Ramus, SJ; Riboli, E; Riggan, MJ; Romieu, I; Sandler, DP; Schildkraut, JM; Setiawan, VW; Sieh, W; Song, H; Sutphen, R; Terry, KL; Thompson, PJ; Titus, L; Tworoger, SS; Van Nieuwenhuysen, E; Edwards, DV; Webb, PM; Wentzensen, N; Whittemore, AS; Wolk, A; Wu, AH; Ziogas, A; Freedman, ML; Lawrenson, K; Pharoah, PDP; Easton, DF; Gayther, SA; Jones, MR
MLA Citation
DeVries, Amber A., et al. “Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.” J Natl Cancer Inst, vol. 114, no. 11, Nov. 2022, pp. 1533–44. Pubmed, doi:10.1093/jnci/djac160.
URI
https://scholars.duke.edu/individual/pub1553218
PMID
36210504
Source
pubmed
Published In
J Natl Cancer Inst
Volume
114
Published Date
Start Page
1533
End Page
1544
DOI
10.1093/jnci/djac160
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.
BACKGROUND: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. METHODS: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. RESULTS: LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. CONCLUSIONS: LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.
Authors
Fu, Z; Brooks, MM; Irvin, S; Jordan, S; Aben, KKH; Anton-Culver, H; Bandera, EV; Beckmann, MW; Berchuck, A; Brooks-Wilson, A; Chang-Claude, J; Cook, LS; Cramer, DW; Cushing-Haugen, KL; Doherty, JA; Ekici, AB; Fasching, PA; Fortner, RT; Gayther, SA; Gentry-Maharaj, A; Giles, GG; Goode, EL; Goodman, MT; Harris, HR; Hein, A; Kaaks, R; Kiemeney, LA; Köbel, M; Kotsopoulos, J; Le, ND; Lee, AW; Matsuo, K; McGuire, V; McLaughlin, JR; Menon, U; Milne, RL; Moysich, KB; Pearce, CL; Pike, MC; Qin, B; Ramus, SJ; Riggan, MJ; Rothstein, JH; Schildkraut, JM; Sieh, W; Sutphen, R; Terry, KL; Thompson, PJ; Titus, L; van Altena, AM; White, E; Whittemore, AS; Wu, AH; Zheng, W; Ziogas, A; Taylor, SE; Tang, L; Songer, T; Wentzensen, N; Webb, PM; AOCS Group,; Risch, HA; Modugno, F
MLA Citation
Fu, Zhuxuan, et al. “Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.” J Natl Cancer Inst, vol. 115, no. 5, May 2023, pp. 539–51. Pubmed, doi:10.1093/jnci/djad011.
URI
https://scholars.duke.edu/individual/pub1563746
PMID
36688720
Source
pubmed
Published In
J Natl Cancer Inst
Volume
115
Published Date
Start Page
539
End Page
551
DOI
10.1093/jnci/djad011
Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD study.
BACKGROUND: Racial and ethnic disparities in ovarian cancer (OC) survival are well-documented. However, few studies have investigated how health-care access (HCA) contributes to these disparities. METHODS: To evaluate the influence of HCA on OC mortality, we analyzed 2008-2015 Surveillance, Epidemiology, and End Results-Medicare data. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between HCA dimensions (affordability, availability, accessibility) and OC-specific and all-cause mortality, adjusting for patient characteristics and treatment receipt. RESULTS: The study cohort included 7590 OC patients: 454 (6.0%) Hispanic, 501 (6.6%) Non-Hispanic (NH) Black, and 6635 (87.4%) NH White. Higher affordability (HR = 0.90, 95% CI = 0.87 to 0.94), availability (HR = 0.95, 95% CI = 0.92 to 0.99), and accessibility scores (HR = 0.93, 95% CI = 0.87 to 0.99) were associated with lower risk of OC mortality after adjusting for demographic and clinical factors. Racial disparities were observed after additional adjustment for these HCA dimensions: NH Black patients experienced a 26% higher risk of OC mortality compared with NH White patients (HR = 1.26, 95% CI = 1.11 to 1.43) and a 45% higher risk among patients who survived at least 12 months (HR = 1.45, 95% CI = 1.16 to 1.81). CONCLUSIONS: HCA dimensions are statistically significantly associated with mortality after OC and explain some, but not all, of the observed racial disparity in survival of patients with OC. Although equalizing access to quality health care remains critical, research on other HCA dimensions is needed to determine additional factors contributing to disparate OC outcomes by race and ethnicity and advance the field toward health equity.
Authors
Montes de Oca, MK; Chen, Q; Howell, E; Wilson, LE; Meernik, C; Previs, RA; Huang, B; Pisu, M; Liang, MI; Ward, KC; Schymura, MJ; Berchuck, A; Akinyemiju, T
MLA Citation
Montes de Oca, Mary Katherine, et al. “Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD study.” Jnci Cancer Spectr, vol. 7, no. 2, Mar. 2023. Pubmed, doi:10.1093/jncics/pkad011.
URI
https://scholars.duke.edu/individual/pub1566653
PMID
36794910
Source
pubmed
Published In
Jnci Cancer Spectrum
Volume
7
Published Date
DOI
10.1093/jncics/pkad011
Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation.
IMPORTANCE: Poor health care access (HCA) is associated with racial and ethnic disparities in ovarian cancer (OC) survival. OBJECTIVE: To generate composite scores representing health care affordability, availability, and accessibility via factor analysis and to evaluate the association between each score and key indicators of guideline-adherent care. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from patients with OC diagnosed between 2008 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) Medicare database. The SEER Medicare database uses cancer registry data and linked Medicare claims from 12 US states. Included patients were Hispanic, non-Hispanic Black, and non-Hispanic White individuals aged 65 years or older diagnosed from 2008 to 2015 with first or second primary OC of any histologic type (International Classification of Diseases for Oncology, 3rd Edition [ICD-O-3] code C569). Data were analyzed from June 2020 to June 2022. EXPOSURES: The SEER-Medicare data set was linked with publicly available data sets to obtain 35 variables representing health care affordability, availability, and accessibility. A composite score was created for each dimension using confirmatory factor analysis followed by a promax (oblique) rotation on multiple component variables. MAIN OUTCOMES AND MEASURES: The main outcomes were consultation with a gynecologic oncologist for OC and receipt of OC-related surgery in the 2 months prior to or 6 months after diagnosis. RESULTS: The cohort included 8987 patients, with a mean (SD) age of 76.8 (7.3) years and 612 Black patients (6.8%), 553 Hispanic patients (6.2%), and 7822 White patients (87.0%). Black patients (adjusted odds ratio [aOR], 0.75; 95% CI, 0.62-0.91) and Hispanic patients (aOR, 0.81; 95% CI, 0.67-0.99) were less likely to consult a gynecologic oncologist compared with White patients, and Black patients were less likely to receive surgery after adjusting for demographic and clinical characteristics (aOR, 0.76; 95% CI, 0.62-0.94). HCA availability and affordability were each associated with gynecologic oncologist consultation (availability: aOR, 1.16; 95% CI, 1.09-1.24; affordability: aOR, 1.13; 95% CI, 1.07-1.20), while affordability was associated with receipt of OC surgery (aOR, 1.08; 95% CI, 1.01-1.15). In models mutually adjusted for availability, affordability, and accessibility, Black patients remained less likely to consult a gynecologic oncologist (aOR, 0.80; 95% CI, 0.66-0.97) and receive surgery (aOR, 0.80; 95% CI, 0.65-0.99). CONCLUSIONS AND RELEVANCE: In this cohort study of Hispanic, non-Hispanic Black, and non-Hispanic White patients with OC, HCA affordability and availability were significantly associated with receiving surgery and consulting a gynecologic oncologist. However, these dimensions did not fully explain racial and ethnic disparities.
Authors
Gupta, A; Chen, Q; Wilson, LE; Huang, B; Pisu, M; Liang, M; Previs, RA; Moss, HA; Ward, KC; Schymura, MJ; Berchuck, A; Akinyemiju, TF
MLA Citation
Gupta, Anjali, et al. “Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation.” Jama Netw Open, vol. 6, no. 2, Feb. 2023, p. e2254595. Pubmed, doi:10.1001/jamanetworkopen.2022.54595.
URI
https://scholars.duke.edu/individual/pub1564979
PMID
36723938
Source
pubmed
Published In
Jama Network Open
Volume
6
Published Date
Start Page
e2254595
DOI
10.1001/jamanetworkopen.2022.54595
Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.
IMPORTANCE: Frequent aspirin use is associated with reduced ovarian cancer risk, but it is unknown whether genetic factors modify this association. Understanding effect modifiers is important given that any use of aspirin for ovarian cancer chemoprevention will likely need to focus on specific higher-risk subgroups. OBJECTIVE: To evaluate whether the association between frequent aspirin use and ovarian cancer is modified by a polygenic score (PGS) for nonmucinous ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: We pooled individual-level data from 8 population-based case-control studies from the Ovarian Cancer Association Consortium conducted in the US, UK, and Australia between 1995 and 2009. We included case patients and control participants with both genetic data and data on frequent aspirin use. Case patients with mucinous ovarian cancer were excluded. Data were analyzed between November 1, 2021, and July 31, 2022. EXPOSURES: Frequent aspirin use, defined as daily or almost daily use for 6 months or longer. MAIN OUTCOMES AND MEASURES: The main outcome was nonmucinous epithelial ovarian cancer. We used logistic regression to estimate odds ratios (ORs) and 95% CIs and likelihood ratio tests to investigate effect modification by the PGS. RESULTS: There were 4476 case patients with nonmucinous ovarian cancer and 6659 control participants included in this analysis. At study enrollment, the median (IQR) age was 58 (50-66) years for case patients and 57 (49-65) years for control participants. Case patients and control participants self-reported that they were Black (122 [3%] vs 218 [3%]), White (3995 [89%] vs 5851 [88%]), or of other race and ethnicity (348 [8%] vs 580 [9%]; race and ethnicity were unknown for 11 [0%] vs 10 [0%]). There were 575 case patients (13%) and 1030 control participants (15%) who reported frequent aspirin use. The 13% reduction in ovarian cancer risk associated with frequent aspirin use (OR, 0.87 [95% CI, 0.76-0.99]) was not modified by the PGS. Consistent ORs were observed among individuals with a PGS less than (0.85 [0.70-1.02]) and greater than (0.86 [0.74-1.01]) the median. Results were similar by histotype. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that genetic susceptibility to ovarian cancer based on currently identified common genetic variants does not appear to modify the protective association between frequent aspirin use and ovarian cancer risk. Future work should continue to explore the role of aspirin use for ovarian cancer prevention among individuals who are at higher risk for ovarian cancer.
Authors
Hurwitz, LM; Webb, PM; Jordan, SJ; Doherty, JA; Harris, HR; Goodman, MT; Shvetsov, YB; Modugno, F; Moysich, KB; Schildkraut, JM; Berchuck, A; Anton-Culver, H; Ziogas, A; Menon, U; Ramus, SJ; Wu, AH; Pearce, CL; Wentzensen, N; Tworoger, SS; Pharoah, PDP; Trabert, B
MLA Citation
Hurwitz, Lauren M., et al. “Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.” Jama Netw Open, vol. 6, no. 2, Feb. 2023, p. e230666. Pubmed, doi:10.1001/jamanetworkopen.2023.0666.
URI
https://scholars.duke.edu/individual/pub1566893
PMID
36826816
Source
pubmed
Published In
Jama Network Open
Volume
6
Published Date
Start Page
e230666
DOI
10.1001/jamanetworkopen.2023.0666
Research Areas:
3' Untranslated Regions
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
5-Lipoxygenase-Activating Proteins
ABO Blood-Group System
ATP-Binding Cassette, Sub-Family B, Member 1
Acetaminophen
Actins
Actomyosin
Actuarial Analysis
Adaptor Proteins, Signal Transducing
Adenocarcinoma
Adenocarcinoma, Clear Cell
Adenocarcinoma, Mucinous
Adnexa Uteri
Adnexal Diseases
Adolescent
Adult
African Americans
African Continental Ancestry Group
Age Distribution
Age Factors
Age of Onset
Aged
Aged, 80 and over
Alcohol Dehydrogenase
Algorithms
Alkylating Agents
Alleles
Alternative Splicing
Americas
Amidohydrolases
Amino Acid Sequence
Aminopeptidases
Amnion
Analysis of Variance
Anemia
Aneuploidy
Angiogenic Proteins
Animals
Anthropometry
Anti-Inflammatory Agents, Non-Steroidal
Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antidepressive Agents
Antigens, CD
Antigens, CD31
Antigens, CD45
Antigens, CD80
Antigens, Tumor-Associated, Carbohydrate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Apolipoprotein A-I
Apoptosis
Apoptosis Regulatory Proteins
Arylamine N-Acetyltransferase
Ascites
Ascitic Fluid
Autophagy
Azacitidine
B7-1 Antigen
BRCA1 Protein
BRCA2 Protein
Base Sequence
Bayes Theorem
Binding Sites
Biopsy
Biopsy, Needle
Blood Coagulation
Blood Coagulation Disorders
Blood Coagulation Tests
Blood Loss, Surgical
Blood Transfusion
Blotting, Northern
Blotting, Southern
Blotting, Western
Body Height
Body Mass Index
Bone Marrow Transplantation
Brachytherapy
Brain Neoplasms
Breast
Breast Neoplasms
CA-125 Antigen
Cadherins
Caloric Restriction
Cancer
Carbon-Nitrogen Ligases
Carboplatin
Carcinoembryonic Antigen
Carcinoma
Carcinoma in Situ
Carcinoma, Adenoid Cystic
Carcinoma, Endometrioid
Carcinoma, Papillary
Carcinoma, Signet Ring Cell
Carcinoma, Small Cell
Carcinoma, Squamous Cell
Carcinosarcoma
Carrier Proteins
Case-Control Studies
Caspase 3
Caspase 8
Catalytic Domain
Cell Adhesion
Cell Culture Techniques
Cell Cycle
Cell Cycle Proteins
Cell Division
Cell Growth Processes
Cell Line
Cell Line, Transformed
Cell Line, Tumor
Cell Lineage
Cell Movement
Cell Proliferation
Cell Shape
Cell Survival
Cell Transformation, Neoplastic
Cells, Cultured
Cervix Uteri
Cesarean Section
Chemotherapy
Chemotherapy, Adjuvant
Chi-Square Distribution
Chickens
Child
Child, Preschool
Chloramphenicol O-Acetyltransferase
Choriocarcinoma
Chorionic Gonadotropin
Chromatin
Chromatography, Affinity
Chromatography, Liquid
Chromium
Chromium Compounds
Chromosome Aberrations
Chromosome Deletion
Chromosome Mapping
Chromosomes, Human, Pair 1
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 17
Chromosomes, Human, Pair 18
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 2
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 4
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 9
Cisplatin
Clinical Competence
Clinical Trials as Topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clone Cells
Cloning, Molecular
Cluster Analysis
Codon
Cohort Studies
Coitus
Colectomy
Collagen
Colon
Colon, Sigmoid
Colonic Neoplasms
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Combined Modality Therapy
Comparative Effectiveness Research
Comparative Genomic Hybridization
Compliance
Condylomata Acuminata
Confidence Intervals
Confounding Factors (Epidemiology)
Contraception
Contraceptives, Oral
Contraceptives, Oral, Combined
Contraceptives, Oral, Hormonal
Cooperative Behavior
Cost-Benefit Analysis
Counseling
CpG Islands
Culture Media
Cyclin E
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinases
Cyclins
Cyclophosphamide
Cystadenocarcinoma
Cystadenocarcinoma, Papillary
Cystadenocarcinoma, Serous
Cystadenoma, Mucinous
Cystadenoma, Serous
Cysts
Cytochrome P-450 CYP1A1
Cytochrome P-450 CYP3A
Cytokines
Cytostatic Agents
DNA
DNA (Cytosine-5-)-Methyltransferase
DNA (Cytosine-5-)-Methyltransferases
DNA Copy Number Variations
DNA Damage
DNA Fingerprinting
DNA Helicases
DNA Ligases
DNA Methylation
DNA Mismatch Repair
DNA Mutational Analysis
DNA Polymerase II
DNA Primers
DNA Repair
DNA, Complementary
DNA, Neoplasm
DNA, Satellite
DNA, Single-Stranded
DNA-Binding Proteins
Dactinomycin
Data Collection
Decision Support Techniques
Decision Trees
Deoxyribonucleases, Type II Site-Specific
Depression, Chemical
Dermatologic Surgical Procedures
Developed Countries
Diacylglycerol Kinase
Diagnosis, Differential
Diet
Dietary Supplements
Diffusion of Innovation
Dihydrouracil Dehydrogenase (NADP)
Dinoprostone
Diploidy
Discriminant Analysis
Disease Models, Animal
Disease Progression
Disease-Free Survival
Diseases
Dormancy
Dosage Compensation, Genetic
Dose-Response Relationship, Drug
Down-Regulation
Doxorubicin
Drug Administration Schedule
Drug Combinations
Drug Design
Drug Resistance
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Drug Synergism
E2F Transcription Factors
Early Detection of Cancer
Education, Medical, Graduate
Eflornithine
Eggs
Electrophoresis, Polyacrylamide Gel
Endometrial Hyperplasia
Endometrial Neoplasms
Endometriosis
Endometrium
Endosomal Sorting Complexes Required for Transport
Environmental Exposure
Enzyme Induction
Enzyme Inhibitors
Enzyme-Linked Immunosorbent Assay
Epidermal Growth Factor
Epigenesis, Genetic
Epigenomics
Epithelial Cells
Epithelium
Epitopes
Epoxide Hydrolases
Estradiol
Estrogen Antagonists
Estrogen Receptor alpha
Estrogen Receptor beta
Estrogen Replacement Therapy
Estrogens
Ethics, Medical
Ethnic Groups
Etoposide
Europe
European Continental Ancestry Group
Evaluation Studies as Topic
Exome
Exons
Extracellular Space
Factor IX
Fallopian Tube Neoplasms
Fallopian Tubes
Family planning
Fatigue
Fellowships and Scholarships
Female
Fetal Diseases
Fibrin Fibrinogen Degradation Products
Fibroblast Growth Factor 2
Fibroblast Growth Factors
Fibroblasts
Fibronectins
Fistula
Flow Cytometry
Fluorescent Antibody Technique
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Folate Receptor 1
Folate Receptors, GPI-Anchored
Folic Acid
Follow-Up Studies
Forecasting
Formaldehyde
Frozen Sections
G1 Phase
GPI-Linked Proteins
GTP Phosphohydrolases
GTP-Binding Proteins
Galectin 1
Galectin 3
Gastrointestinal Diseases
Gene Amplification
Gene Deletion
Gene Dosage
Gene Expression
Gene Expression Profiling
Gene Expression Regulation
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Gene Frequency
Gene Silencing
Gene Transfer Techniques
Gene-Environment Interaction
Genes, BRCA1
Genes, BRCA2
Genes, Neoplasm
Genes, Tumor Suppressor
Genes, cdc
Genes, fms
Genes, p16
Genes, p53
Genes, ras
Genetic Association Studies
Genetic Heterogeneity
Genetic Linkage
Genetic Loci
Genetic Markers
Genetic Predisposition to Disease
Genetic Testing
Genetic Therapy
Genetic Variation
Genetics
Genital Diseases, Female
Genital Neoplasms, Female
Genome, Human
Genome-Wide Association Study
Genomic Imprinting
Genomic Instability
Genomics
Genotype
Germ-Line Mutation
Glycoproteins
Gonadotropins
Granulocyte Colony-Stimulating Factor
Gravity Suits
Great Britain
Green Fluorescent Proteins
Growth Inhibitors
Growth Substances
Gynecologic Surgical Procedures
Gynecology
Half-Life
Haplotypes
HeLa Cells
Head and Neck Neoplasms
Health Care Costs
Health Planning Guidelines
Health Resources
Hemagglutinins
Hemorrhage
Heparin
Hepatocyte Nuclear Factor 1-beta
Heterocyclic Compounds with 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
Heterozygote
Histones
Homeodomain Proteins
Homozygote
Hormone Replacement Therapy
Hormones
Humans
Hybrid Cells
Hydatidiform Mole
Hydrolysis
Hyperthermia, Induced
Hysterectomy
Image Processing, Computer-Assisted
Immunity
Immunoassay
Immunoblotting
Immunoenzyme Techniques
Immunohistochemistry
Immunologic Factors
Immunoradiometric Assay
Immunosuppressive Agents
Immunotherapy
Immunotoxins
In Situ Hybridization
Incidence
Infant
Infant, Newborn
Infection
Inflammation
Infusions, Parenteral
Injections, Intramuscular
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Integrins
Intercellular Signaling Peptides and Proteins
Interferon-gamma
Interleukin-1
Interleukin-18
Interleukin-1alpha
Interleukin-6
International Agencies
International Cooperation
Internship and Residency
Interviews as Topic
Intracellular Signaling Peptides and Proteins
Intraoperative Complications
Introns
Kaplan-Meier Estimate
Keratins
Ki-67 Antigen
Kidney Diseases
Kinetics
Laminin
Laparoscopy
Laparotomy
Leiomyoma
Leiomyosarcoma
Length of Stay
Leucine Zippers
Leukocyte Common Antigens
Life Expectancy
Life Tables
Linear Models
Linkage Disequilibrium
Liver Diseases
Logistic Models
Longitudinal Studies
Loss of Heterozygosity
Lovastatin
Luciferases
Luminescent Proteins
Lung Diseases
Lung Neoplasms
Lymph Node Excision
Lymph Nodes
Lymphatic Diseases
Lymphatic Metastasis
Lymphedema
Lymphocyte Activation
Lymphocytes
Lymphocytes, Tumor-Infiltrating
Lysophospholipids
MAP Kinase Kinase 4
MAP Kinase Signaling System
Macaca fascicularis
Macrophage Colony-Stimulating Factor
Magnetics
Male
Mammary Neoplasms, Experimental
Marketing
Markov Chains
Matrix Metalloproteinase 1
Maximum Tolerated Dose
Medical History Taking
Medical Oncology
Medicine
Mefenamic Acid
Membrane Glycoproteins
Membrane Proteins
Membrane Transport Proteins
Menarche
Menopause
Menstrual Cycle
Menstruation Disturbances
Meta-Analysis as Topic
Metabolic Clearance Rate
Methods
Methotrexate
Methylation
Methylenetetrahydrofolate Dehydrogenase (NADP)
Mice
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
Microarray Analysis
Microfilament Proteins
Micromanipulation
Microsatellite Instability
Microsatellite Repeats
Microscopy, Atomic Force
Microscopy, Confocal
Microscopy, Electron
Microspheres
Middle Aged
Mitochondrial Proteins
Mitosis
Mitotic Index
Mixed Tumor, Mesodermal
Mixed Tumor, Mullerian
Models, Biological
Models, Economic
Models, Genetic
Models, Statistical
Molecular Conformation
Molecular Sequence Data
Molecular Targeted Therapy
Molecular Weight
Morbidity
Mucin-1
Mullerian Ducts
Multicenter Studies as Topic
Multivariate Analysis
Muscle, Skeletal
MutS Homolog 2 Protein
Mutagenesis, Insertional
Mutation
Mycobacterium bovis
Myelin Proteins
Myelin and Lymphocyte-Associated Proteolipid Proteins
Myometrium
Myosin Type II
N-Acetylgalactosaminyltransferases
NAD(P)H Dehydrogenase (Quinone)
NF-kappa B
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasm Proteins
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Transplantation
Neoplasm, Residual
Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Multiple Primary
Neoplasms, Second Primary
Neoplastic Stem Cells
Neoplastic Syndromes, Hereditary
Neovascularization, Pathologic
Nerve Tissue Proteins
Neural Networks (Computer)
Neuropeptides
Neutropenia
Nicotinic Acids
North America
North Carolina
Nuclear Proteins
Nuclear Receptor Co-Repressor 1
Nuclear Receptor Co-Repressor 2
Nucleic Acid Heteroduplexes
Nucleic Acid Hybridization
Nutrition Disorders
Obesity
Observer Variation
Odds Ratio
Oligodeoxyribonucleotides
Oligonucleotide Array Sequence Analysis
Oligonucleotide Probes
Omentum
Oncogene Proteins, Viral
Oncogenes
Oncology Service, Hospital
Ornithine Decarboxylase
Ovarian Cysts
Ovarian Diseases
Ovarian Neoplasms
Ovariectomy
Ovary
Oviducts
Ovulation
Oxytocin
P-Glycoprotein
PTEN Phosphohydrolase
Paclitaxel
Pain, Postoperative
Palliative Care
Papillomaviridae
Paraffin Embedding
Parity
Patient Acceptance of Health Care
Patient Selection
Pedigree
Pelvic Exenteration
Pelvic Neoplasms
Pelvis
Peptide Elongation Factor Tu
Peptide Termination Factors
Peptides
Peripheral Nervous System Diseases
Peritoneal Cavity
Peritoneal Diseases
Peritoneal Lavage
Peritoneal Neoplasms
Peritoneum
Peritonitis, Tuberculous
Pharmacogenetics
Phenotype
Phosphates
Phosphatidate Phosphatase
Phosphatidylinositol 3-Kinases
Phosphoproteins
Phosphoric Monoester Hydrolases
Phosphorus Radioisotopes
Phosphorylation
Physical Examination
Pilot Projects
Piperidines
Placenta Accreta
Platelet Endothelial Cell Adhesion Molecule-1
Platelet-Derived Growth Factor
Platinum
Platinum Compounds
Ploidies
Pneumoperitoneum
Point Mutation
Poly(ADP-ribose) Polymerases
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Polymorphism, Single Nucleotide
Polymorphism, Single-Stranded Conformational
Population Dynamics
Population Surveillance
Postmenopause
Postoperative Complications
Postoperative Period
Powders
Practice Guidelines as Topic
Prealbumin
Precancerous Conditions
Precipitin Tests
Predictive Value of Tests
Pregnancy
Pregnancy Complications
Pregnancy Tests
Pregnancy Trimester, Second
Premenopause
Prenatal Diagnosis
Preoperative Care
Prevalence
Principal Component Analysis
Probability
Progesterone
Progestins
Prognosis
Proliferating Cell Nuclear Antigen
Promoter Regions, Genetic
Proportional Hazards Models
Prospective Studies
Prostaglandins
Prostaglandins E
Prostatic Neoplasms
Protamine Kinase
Protective Agents
Protein Array Analysis
Protein Isoforms
Protein Kinase C
Protein Kinase C-delta
Protein Kinase Inhibitors
Protein Precursors
Protein Processing, Post-Translational
Protein Structure, Tertiary
Protein Tyrosine Phosphatases
Protein-Serine-Threonine Kinases
Protein-Tyrosine Kinases
Proteins
Proteoglycans
Proteolipids
Proteomics
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myb
Proto-Oncogene Proteins pp60(c-src)
Proto-Oncogenes
Purines
Pyrimidines
Quality Control
Quality of Life
Quality-Adjusted Life Years
Quantitative Trait Loci
Questionnaires
Quinone Reductases
RNA
RNA Splicing
RNA, Antisense
RNA, Messenger
RNA, Neoplasm
RNA, Small Interfering
RNA, Untranslated
ROC Curve
Radiation Injuries
Radioimmunoassay
Radioimmunoprecipitation Assay
Radiopharmaceuticals
Radiotherapy
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Rats
Rats, Sprague-Dawley
Real-Time Polymerase Chain Reaction
Receptor Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Receptor, IGF Type 2
Receptor, erbB-2
Receptors, Androgen
Receptors, Calcitriol
Receptors, Cell Surface
Receptors, Estrogen
Receptors, Growth Factor
Receptors, Interleukin-1
Receptors, Interleukin-2
Receptors, Laminin
Receptors, Progesterone
Receptors, Transforming Growth Factor beta
Receptors, Tumor Necrosis Factor
Reconstructive Surgical Procedures
Rectus Abdominis
Recurrence
Reference Values
Registries
Regression Analysis
Remission Induction
Reoperation
Repetitive Sequences, Amino Acid
Repetitive Sequences, Nucleic Acid
Repressor Proteins
Reproducibility of Results
Reproductive History
Retinoblastoma Protein
Retirement
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Ricin
Risk
Risk Assessment
Risk Factors
Risk Reduction Behavior
Robotics
SEER Program
Sarcoma
Second-Look Surgery
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Sequence Analysis, DNA
Sequence Deletion
Serpins
Signal Transduction
Skin
Societies, Medical
Societies, Scientific
Socioeconomic Factors
Solubility
Specialization
Spheroids, Cellular
Staining and Labeling
Statistics, Nonparametric
Staurosporine
Sterilization, Tubal
Stimulation, Chemical
Stromal Cells
Sulfites
Surgical Flaps
Surgical Wound Dehiscence
Surgical Wound Infection
Surveys and Questionnaires
Survival
Survival Analysis
Survival Rate
Survivors
Sutures
T-Lymphocytes, Regulatory
TNF-Related Apoptosis-Inducing Ligand
Talc
Tamoxifen
Tandem Mass Spectrometry
Taxoids
Telomerase
Telomere
Terminal Care
Testis
Tetradecanoylphorbol Acetate
Tetrahydronaphthalenes
Therapies, Investigational
Thiazoles
Thigh
Thioguanine
Thiophenes
Thiotepa
Thrombocytosis
Thrombophlebitis
Thrombosis
Thrombospondin 1
Thymidine
Thymidylate Synthase
Time Factors
Tissue Array Analysis
Tissue Distribution
Tissue Embedding
Tissue Fixation
Tomography, Emission-Computed
Tomography, X-Ray Computed
Trans-Activators
Transcription Factors
Transcription, Genetic
Transcriptional Activation
Transfection
Transforming Growth Factor alpha
Transforming Growth Factor beta
Transforming Growth Factor beta1
Transforming Growth Factors
Transplantation, Autologous
Treatment Outcome
Tretinoin
Trinucleotide Repeats
Tritium
Trophoblastic Neoplasms
Tumor Cells, Cultured
Tumor Markers, Biological
Tumor Necrosis Factor-alpha
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
United Kingdom
United States
Up-Regulation
Urologic Diseases
Utah
Uterine Cervical Diseases
Uterine Cervical Incompetence
Uterine Cervical Neoplasms
Uterine Hemorrhage
Uterine Neoplasms
Uterine Rupture
Uterus
Vagina
Vaginal Fistula
Vaginal Neoplasms
Vaginal Smears
Vanadates
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Venous Thrombosis
Vincristine
Vulva
Vulvar Neoplasms
Wound Healing
X Chromosome
X-Linked Inhibitor of Apoptosis Protein
Xenobiotics
YY1 Transcription Factor
Young Adult
alpha-Fetoproteins
bcl-Associated Death Protein
ras Proteins
rho GTP-Binding Proteins
src-Family Kinases
James M. Ingram Distinguished Professor of Gynecologic Oncology
Contact:
25171 Morris Bldg, Durham, NC 27710
Box 3079 Med Ctr, Durham, NC 27710